Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schindl, M.
Right arrow Articles by Birner, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schindl, M.
Right arrow Articles by Birner, P.
Clinical Cancer Research Vol. 9, 779-785, February 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Level of Id-1 Protein Expression Correlates with Poor Differentiation, Enhanced Malignant Potential, and More Aggressive Clinical Behavior of Epithelial Ovarian Tumors

Monika Schindl1, Sebastian F. Schoppmann1, Thomas Ströbel, Harald Heinzl, Christina Leisser, Reinhard Horvat and Peter Birner2

Institute of Clinical Pathology [M. S., S. F. S., C. L., R. H., P. B.], Institute of Neurology [T. S.], and the Department of Medical Computer Sciences, Section of Clinical Biometrics [H. H.], University of Vienna, A-1090 Vienna, Austria

Purpose: Id (inhibitor of differentiation/DNA binding) -1 is involved in neoangiogenesis, it antagonizes basic helix-loop-helix proteins, inhibits differentiation, and enhances cell proliferation. Aim of this study was to investigate Id-1 protein expression in epithelial ovarian tumors and its clinical relevance in ovarian cancer.

Experimental Design: We have investigated Id-1 expression by reverse transcription-PCR and Western blotting in ovarian cancer samples. On the basis of these results, Id-1 protein expression was determined by immunohistochemistry in 101 specimens of epithelial ovarian cancer, in 40 borderline tumors, and in 20 cystadenomas. In these cases, Id-1 expression was correlated with p21 expression, microvessel density, and survival.

Results: By immunohistochemistry, detectable expression of Id-1 was found significantly more often in ovarian cancers (74.3%) than in borderline tumors (32.5%) and cystadenomas (0%; P < 0.0001, {chi}2 test). Cancer samples with poor or moderate histological differentiation (G3/G2) showed significantly stronger Id-1 expression than cancer samples with high differentiation (G1; P = 0.021, Mann-Whitney test), and no association of Id-1 with p21 expression or microvessel density was found. In cancer samples strong or moderate expression of Id-1 was a strong predictor for shorter overall survival in uni- and multivariate analysis (P = 0.001, Cox-regression).

Conclusions: The level of Id-1 protein expression correlates with the malignant potential of ovarian tumors. In cancer samples, stronger Id-1 expression is associated with poor differentiation and more aggressive behavior of tumor cells, resulting in poor clinical outcome. Consequently, Id-1 inhibition in the future might be of benefit for patients with ovarian cancer.




This article has been cited by other articles:


Home page
J. Histochem. Cytochem.Home page
R. Salomon, L. Young, D. MacLeod, X.-L. Yu, and Q. Dong
Probasin Promoter-driven Expression of ID1 Is not Sufficient for Carcinogenesis in Rodent Prostate
J. Histochem. Cytochem., June 1, 2009; 57(6): 599 - 604.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Qian and X. Chen
ID1, Inhibitor of Differentiation/DNA Binding, Is an Effector of the p53-dependent DNA Damage Response Pathway
J. Biol. Chem., August 15, 2008; 283(33): 22410 - 22416.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Kamalian, J. R. Gosney, S. S. Forootan, C. S. Foster, Z. Z. Bao, C. Beesley, and Y. Ke
Increased Expression of Id Family Proteins in Small Cell Lung Cancer and its Prognostic Significance
Clin. Cancer Res., April 15, 2008; 14(8): 2318 - 2325.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
O. Gautschi, C. G. Tepper, P. R. Purnell, Y. Izumiya, C. P. Evans, T. P. Green, P. Y. Desprez, P. N. Lara, D. R. Gandara, P. C. Mack, et al.
Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer
Cancer Res., April 1, 2008; 68(7): 2250 - 2258.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Tsunedomi, N. Iizuka, T. Tamesa, K. Sakamoto, T. Hamaguchi, H. Somura, M. Yamada, and M. Oka
Decreased ID2 Promotes Metastatic Potentials of Hepatocellular Carcinoma by Altering Secretion of Vascular Endothelial Growth Factor
Clin. Cancer Res., February 15, 2008; 14(4): 1025 - 1031.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Zhang, M.-T. Ling, Q. Wang, C.-K. Lau, S. C. L. Leung, T. K. Lee, A. L. M. Cheung, Y.-C. Wong, and X. Wang
Identification of a Novel Inhibitor of Differentiation-1 (ID-1) Binding Partner, Caveolin-1, and Its Role in Epithelial-Mesenchymal Transition and Resistance to Apoptosis in Prostate Cancer Cells
J. Biol. Chem., November 16, 2007; 282(46): 33284 - 33294.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
F. Moll, C. Millet, D. Noel, B. Orsetti, A. Bardin, D. Katsaros, C. Jorgensen, M. Garcia, C. Theillet, P. Pujol, et al.
Chordin is underexpressed in ovarian tumors and reduces tumor cell motility
FASEB J, February 1, 2006; 20(2): 240 - 250.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M.-T. Ling, T. C.M. Lau, C. Zhou, C. W. Chua, W. K. Kwok, Q. Wang, X. Wang, and Y.-C. Wong
Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF)
Carcinogenesis, October 1, 2005; 26(10): 1668 - 1676.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Kebebew, M. Peng, P. A. Treseler, O. H. Clark, Q.-Y. Duh, D. Ginzinger, and R. Miner
Id1 Gene Expression Is Up-Regulated in Hyperplastic and Neoplastic Thyroid Tissue and Regulates Growth and Differentiation in Thyroid Cancer Cells
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6105 - 6111.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. W. Cheung, M.-t. Ling, S. W. Tsao, Y.C. Wong, and X. Wang
Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells
Carcinogenesis, June 1, 2004; 25(6): 881 - 887.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-P. Coppe, Y. Itahana, D. H. Moore, J. L. Bennington, and P.-Y. Desprez
Id-1 and Id-2 Proteins as Molecular Markers for Human Prostate Cancer Progression
Clin. Cancer Res., March 15, 2004; 10(6): 2044 - 2051.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Fong, Y. Itahana, T. Sumida, J. Singh, J.-P. Coppe, Y. Liu, P. C. Richards, J. L. Bennington, N. M. Lee, R. J. Debs, et al.
Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis
PNAS, November 11, 2003; 100(23): 13543 - 13548.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. K.-W. Lee, K. Man, M.-T. Ling, X.-H. Wang, Y.-C. Wong, C.-M. Lo, R. T.-P. Poon, I. O.-L. Ng, and S.-T. Fan
Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway
Carcinogenesis, November 1, 2003; 24(11): 1729 - 1736.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. G. Shepherd and M. W. Nachtigal
Identification of a Putative Autocrine Bone Morphogenetic Protein-Signaling Pathway in Human Ovarian Surface Epithelium and Ovarian Cancer Cells
Endocrinology, August 1, 2003; 144(8): 3306 - 3314.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.